Genmab A/S Sponsored ADR (NASDAQ: GMAB) Financial Performance and Investor Sentiment

Font: Financial Modeling Prep  • Feb 17, 2026

• Earnings per share of $0.35 fell short of the estimated $0.46, while revenue slightly surpassed expectations at approximately $1.06 billion.
• A 15.1% decline in short interest suggests a positive shift in investor sentiment towards GMAB.
• Institutional investors like Alliancebernstein L.P. have increased their stakes, indicating confidence in the company's potential despite its earnings miss.

Genmab A/S Sponsored ADR (NASDAQ:GMAB) is a biotechnology company focused on developing antibody therapeutics for cancer treatment. Despite its innovative approach, GMAB's recent financial performance has been mixed. On February 17, 2026, GMAB reported earnings per share of $0.35, which fell short of the estimated $0.46. However, the company generated revenue of approximately $1.06 billion, slightly surpassing the estimated $1.055 billion.

In January, GMAB experienced a notable decrease in short interest, with a 15.1% decline to approximately 8.4 million shares by January 30th. This reduction in short interest suggests a shift in investor sentiment, possibly due to the company's financial metrics. GMAB's price-to-earnings (P/E) ratio of 17.76 indicates the market's valuation of its earnings, while its price-to-sales ratio of 8.31 reflects the market's valuation relative to its revenue.

Institutional investors have also been adjusting their positions in GMAB. Alliancebernstein L.P. increased its stake by 2.7%, now holding nearly 11 million shares valued at approximately $336 million. This move indicates confidence in GMAB's potential, despite its earnings miss. The company's enterprise value to sales ratio of 8.20 and enterprise value to operating cash flow ratio of 35.91 provide insight into its valuation and cash flow generation.

GMAB's financial health is further supported by its low debt-to-equity ratio of 0.025, indicating minimal reliance on debt financing. Additionally, the company boasts a strong current ratio of 6.03, highlighting its robust liquidity and ability to cover short-term liabilities. These factors contribute to GMAB's overall financial stability, despite the recent earnings shortfall.